港股異動丨李寧(02331.HK)高開4.58% 由其發起的Trinity Acquisition遞表港交所主板
格隆匯2月4日丨李寧(02331.HK)高開4.58%,報78.8港元,總市值2062億港元。港交所文件1月31日披露,特殊目的收購公司Trinity Acquisition Holdings Ltd.向港交所主板遞交上市申請,發起人為李寧和兩傢俬募股權公司萊恩資本(LionRock)和Astrapto,聯席保薦人、聯席全球協調人及聯席賬簿管理人為摩根大通和瑞信。李寧、LionRock及Astrapto分別擁有已發行的所有B類股份的33%、42%及25%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.